Form D · Biotechnology
Entasis Therapeutics Holdings Inc.
Waltham, MA · CIK 0001724344
Offering snapshot reported Sep 10, 2020 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 27, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 10, 2020 | Initial | $24,999,999 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.31M
- Finders' fees
- $0
- Form D file number
- 021-375226
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cantor Fitzgerald & Co. | 134 | |
| A.G.P. / Alliance Global Partner | 8361 |
Source: Form D, filed Sep 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Altarac | Executive |
| Heather Behanna | Director |
| Michael Gutch | Executive |
| David Hastings | Director |
| Elizabeth Keiley | Executive |
| Howard Mayer | Director |
| David Meek | Director |
| John Mueller | Executive |
| Manoussos Perros | Director, Executive |
| Heather Preston | Director |
| Ruben Tommasi | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
35 Gatehouse Drive
Waltham, MA, 02451
Waltham, MA, 02451